metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-119 LIVER TRANSPLANTATION IN ACUTE ON CHRONIC LIVER FAILURE (ACLF): RESULTS OF...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P-119 LIVER TRANSPLANTATION IN ACUTE ON CHRONIC LIVER FAILURE (ACLF): RESULTS OF THE MAIN TRANSPLANT CENTER OF PERU
Visitas
308
Carmen Ana Cerron Cabezas1, Rosa Luz Lopez Martinez2, Gino Salcedo Bermudez2, Pedro Martin Padilla Machaca1,3, Bertha Eliana Cardenas Ramirez1, Wilmer Bacilio Calderon1, Omar Mantilla Cruzatti1, Jose Rivera Romani1, Alfonso Solar Peche1, Saul Espinoza Rivera1, Carlos Felix Rondon Leyva1
1 Transplant Department, Guillermo Almenara National Hospital, Lima, Perú
2 Intensive Care Unit, Guillermo Almenara National Hospital, Lima, Perú
3 Department of Medicine, San Marcos National University, Lima, Perú
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Tablas (1)
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Acute on chronic liver failure is characterized by acute decompensation of chronic liver disease, associated with different organ failure and, therefore, with high mortality. Management is based on supportive treatment and liver transplantation. Successful liver transplantation in Peru began on March 24, 2000. The ACLF consensus dates back to 2009; the first patient with ACLF transplanted in Peru was performed in January 2015; she was a 61 years old woman with cryptogenic liver cirrhosis with three organ failures, ACLF - 3, with CLIF - C ACLF score of 55 points. This study aimed to stratify the different organ failures involved in acute on chronic liver failure in patients undergoing liver transplantation as treatment.

Materials and Methods

Retrospective, a descriptive study from January 2015 to April 2022, included 72 adult liver transplant patients at the "Guillermo Almenara" Hospital. Patients with Hepatopulmonary Syndrome, Liver retransplant, Combined liver-kidney transplant, Hepatorenal polycystosis, SPLIT and Domino Technique, and Pediatric patients were excluded.

Results

Of the 72 liver transplant patients, 40.3% (29 patients) had ACLF, 12 (41.4%) type 1 patients, 5 (17.2%) type 2 patients, and 12 (41.4%) type 3 patients. Average CLIF C - ACLF 50 points. The most frequent organ failure after hepatic was cerebral with encephalopathy 2 in 12 (41.4%) patients; the next failure was coagulation with INR 2 - <2.5 in 9 (31%) patients.

Conclusions

Liver transplantation represents the optimal and definitive treatment. In our casuistry, 40.3% of cirrhotic patients with ACLF were transplanted, with improvement in organ failure and survival at 28 and 90 days of 100%. The average CLIF C - ACLF score of these patients was 50.4 points, with a maximum of 70 points.

El Texto completo está disponible en PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2021.100441
No mostrar más